BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2708546)

  • 1. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
    Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
    J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind comparator trials with pinacidil, a potassium channel opener.
    Callaghan JT; Goldberg MR; Brunelle R
    Drugs; 1988; 36 Suppl 7():77-82. PubMed ID: 3076139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
    Goldberg MR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension.
    Goldberg MR; Rockhold FW; Offen WW; Dornseif BE
    Clin Pharmacol Ther; 1989 Aug; 46(2):208-18. PubMed ID: 2758730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin.
    Goldberg MR; Sushak CS; Rockhold FW; Thompson WL
    Clin Pharmacol Ther; 1988 Jul; 44(1):78-92. PubMed ID: 3292105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No deterioration of insulin secretion by the potassium channel opener pinacidil in essential hypertension.
    Ligtenberg JJ; Leenaers AD; Van Haeften TW; Smit AJ; Sluiter WJ; Reitsma WD
    J Hum Hypertens; 1996 Apr; 10(4):269-76. PubMed ID: 8736460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and pharmacokinetics of pinacidil after a single dose of a new slow release tablet in healthy volunteers.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1998 Jul; 48(7):730-3. PubMed ID: 9706373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pinacidil with and without hydrochlorothiazide. Dose-response relationships from results of a 4 x 3 factorial design study.
    Goldberg MR; Offen WW
    Drugs; 1988; 36 Suppl 7():83-92. PubMed ID: 3076140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous pinacidil in the acute treatment of hypertension.
    Rijk MC; Thien T
    J Clin Pharmacol; 1987 Jul; 27(7):468-74. PubMed ID: 3308975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive efficacy of pinacidil--automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schirger A; Fisher LD; Shub C; Collins JB; Spiekerman RE
    Eur J Clin Pharmacol; 1986; 31(2):133-41. PubMed ID: 3803413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.
    Friedel HA; Brogden RN
    Drugs; 1990 Jun; 39(6):929-67. PubMed ID: 2196168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
    Lawson K; Barras M; Zazzi-Sudriez E; Martin DJ; Armstrong JM; Hicks PE
    Br J Pharmacol; 1992 Sep; 107(1):58-65. PubMed ID: 1422579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal insulin release during sustained hyperglycaemia in hypokalaemic periodic paralysis: role of the potassium channel opener pinacidil in impaired muscle strength.
    Ligtenberg JJ; Van Haeften TW; Van Der Kolk LE; Smit AJ; Sluiter WJ; Reitsma WD; Links TP
    Clin Sci (Lond); 1996 Nov; 91(5):583-9. PubMed ID: 8942397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.
    Girard P; Saumet JL; Dubois F; Boissel JP
    Eur J Clin Pharmacol; 1993; 44(2):177-82. PubMed ID: 8453963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrocardiographic interactions between pinacidil, a potassium channel opener and class I antiarrhythmic agents in guinea-pig isolated perfused heart.
    Yang Q; Padrini R; Bova S; Piovan D; Magnolfi G
    Br J Pharmacol; 1995 Apr; 114(8):1745-9. PubMed ID: 7599944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propranolol antagonizes coronary artery relaxation by a potassium channel opener.
    Kalsner S
    Life Sci; 1994; 55(14):1109-21. PubMed ID: 7916438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pinacidil on blood pressure, plasma catecholamines and plasma renin activity in essential hypertension.
    Muiesan G; Fariello R; Muiesan ML; Christensen OE
    Eur J Clin Pharmacol; 1985; 28(5):495-9. PubMed ID: 3899669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of antihypertensive, renal hemodynamic, and humoral effects of pinacidil and hydralazine monotherapy.
    Abraham PA; Halstenson CE; Matzke GR; Keane WF
    J Clin Hypertens; 1987 Dec; 3(4):439-51. PubMed ID: 3330986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
    Koliopoulos K; Papadoyannis DE; Karatzas NB
    Eur J Clin Pharmacol; 1984; 27(3):287-9. PubMed ID: 6510455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
    Sterndorff B; Johansen P
    Drugs; 1988; 36 Suppl 7():64-6. PubMed ID: 3076137
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.